Metabolomic Study of Obesity and Its Treatment with Palmitoylated Prolactin-Releasing Peptide Analog in Spontaneously Hypertensive and Normotensive Rats

0504540 - MBÚ 2020 RIV US eng J - Článek v odborném periodiku
Čermáková, Martina - Pelantová, Helena - Neprašová, Barbora - Šedivá, Blanka - Maletínská, L. - Kuneš, Jaroslav - Tomášová, Petra - Železná, B. - Kuzma, Marek
Metabolomic Study of Obesity and Its Treatment with Palmitoylated Prolactin-Releasing Peptide Analog in Spontaneously Hypertensive and Normotensive Rats.
Journal of Proteome Research. Roč. 18, č. 4 (2019), s. 1735-1750. ISSN 1535-3893. E-ISSN 1535-3907
Grant CEP: GA MŠMT(CZ) LO1509; GA ČR(CZ) GA18-10591S
Institucionální podpora: RVO:61388971 ; RVO:67985823
Klíčová slova: NMR * metabolomics * obesity
Obor OECD: Microbiology; Endocrinology and metabolism (including diabetes, hormones) (FGU-C)
Impakt faktor: 4.074, rok: 2019
Způsob publikování: Omezený přístup
https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.8b00964

In this study, the combination of metabolomics and standard biochemical and biometric parameters was used to describe the metabolic effects of diet-induced obesity and its treatment with the novel antiobesity compound palm(11)-PrRP31 (palmitoylated prolactin-releasing peptide) in spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY). The results showed that SHR on a high-fat (HF) diet were normoglycemic with obesity and hypertension, while WKY on the HF diet were normotensive and obese with prediabetes. NMR-based metabolomics revealed mainly several microbial cometabolites altered by the HF diet, particularly in urine. The HF diet induced similar changes in both models. However, two groups of genotype-specific metabolites were defined: metabolites specific to the genotype at baseline (e.g., 1-methylnicotinamide, phenylacetylglycine, taurine, methylamine) and metabolites reacting specifically to the HF diet in individual genotypes (2-oxoglutarate, dimethylamine, N-butyrylglycine, p-cresyl sulfate). The palm(11)-PrRP31 lowered body weight and improved biochemical and biometric parameters in both strains, and it improved glucose tolerance in WKY rats on the HF diet. In urine, the therapy induced significant decrease of formate and 1-methylnicotinamide in SHR and alanine, allantoin, dimethylamine, and N-butyrylglycine in WKY. Altogether, our study confirms the effectiveness of palm(11)-PrRP31 for antiobesity treatment.
Trvalý link: http://hdl.handle.net/11104/0296150